A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors
- Resource Type
- Article
- Source
- In
Cancer Treatment and Research Communications 2021 27 - Subject
- Language
- ISSN
- 2468-2942